Fact checks · Stem cells and clinics
“Can a stem cell transplant reset my immune system and stop MS?”
The bottom line
Specialist aHSCT can produce lasting remission in selected people with highly active relapsing MS, but carries serious risks and must not be confused with unsupported commercial stem-cell infusions.
Why people are talking about it
Reports of prolonged remission after transplantation have attracted attention because treatment can sometimes control inflammatory MS without ongoing disease-modifying therapy (DMT). Commercial stem-cell marketing can blur the distinction between this intensive transplant procedure and unrelated cell infusions.
What the research says
aHSCT uses chemotherapy-based immune suppression followed by a person's own blood-forming stem cells to restore blood and immune-cell production. It is not a treatment that directly replaces damaged nerves. In Mancardi and colleagues' ASTIMS phase 2 randomized trial, 21 participants received aHSCT or mitoxantrone, and 17 had evaluable follow-up MRI scans. Transplantation reduced new T2 lesions by 79% relative to mitoxantrone, but the trial found no difference in disability progression. Nash and colleagues' uncontrolled HALT-MS phase 2 study treated 24 people with relapsing-remitting MS, with estimated five-year event-free survival of 69.2%, combining freedom from death, disability progression, relapse and new MRI activity. BEAT-MS is a randomized, assessor-masked comparison with best available therapy, with planned enrollment of 156, rather than completed evidence of superiority over contemporary high-efficacy DMTs. The 2025 ECTRIMS-EBMT recommendations recognize aHSCT as a treatment option for selected treatment-refractory relapsing MS, so this verdict concerns broad claims of a superior treatment or cure, not whether aHSCT has any established clinical role.
What we don't know yet
Its comparative long-term benefits and harms against today's highest-efficacy DMTs remain important questions. Benefit in progressive MS without ongoing inflammatory activity is much less certain, and remission does not establish that existing nerve damage has been repaired.
Risks and costs
Chemotherapy and transplantation can cause severe infections, infertility, organ toxicity and treatment-related death. Treatment also requires substantial recovery time, specialist follow-up and financial planning for care, travel and time away from work. Unsupported clinics, whether overseas or domestic, should not be assumed to reproduce trial protocols or outcomes. Geography alone does not establish quality. Do not stop a proven DMT independently, because any treatment washout or transition needs a coordinated neurologist-transplant plan.
Questions to bring to your neurologist
- Does my disease activity and treatment history make me a suitable candidate for specialist aHSCT assessment?
- How do this centre's protocol, accreditation, complications and long-term outcomes compare with the trial evidence?
- What are my alternatives, fertility-preservation options and DMT transition and follow-up plans?
Sources
- Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial (RCT, 2015)
- High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS (Observational, 2017)
- Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) (Registry, 2019)
- Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT (Review, 2025)
- Important Patient and Consumer Information About Regenerative Medicine Therapies (Regulatory, 2021)
This is information, not medical advice. Talk to your neurologist before changing anything.
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error